Corporate
2025.10.28
Lumosa Share Positive P2 Trial Results
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001 (INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
Corporate
2025.10.17
Announcement: Change in Company Spokesperson
Corporate
2023.09.26
Lumosa's LT1001 Receives Approval from Brunei
Expanding its presence in Southeast Asian market
Corporate
2023.07.26
LT3001 Received Formulation Patent from USPTO
Corporate
2023.05.15
Lumosa’s LT1001 Received First European Approval from Ukraine’s SMDC
Corporate
2023.04.19
First subject for LT3001 Phase 2 trial enrolled in China